Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 20/20 | 0.79 |
| ▸ | DRD2 | P14416 | 16/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365347 | 0.89 | DRD3 (0.73) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL3364328 | 0.89 | DRD3 (0.73) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL3365350 | 0.89 | DRD3 (0.73) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL13114707 | 0.89 | DRD3 (0.73) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL3422939 | 0.88 | DRD3 (0.72) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL3365418 | 0.88 | DRD3 (0.72) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL378168 | 0.87 | DRD3 (1.00) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL3365075 | 0.87 | DRD3 (0.71) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL3365070 | 0.87 | DRD3 (0.71) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL378874 | 0.87 | DRD3 (0.98) | DRD3KCNH2DRD2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891056-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2010-10-13 | — | — | EP | claimed |
| US-7807698-B2 | Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor | GLAXO GROUP LIMITED (GB) | 2010-10-05 | — | — | US | claimed |
| US-20080227837-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | US | claimed |
| EP-1891056-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2010-10-13 | — | — | EP | disclosed |
| US-7807698-B2 | Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor | GLAXO GROUP LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-7807698-B2 | Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor | GLAXO GROUP LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-7807698-B2 | Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor | GLAXO GROUP LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-20080227837-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| US-20080227837-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| US-20080227837-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227837-A1 | Novel Compounds | HTR5A, NPY5R, DRD3 | DRD3 3/4885KCNH2 194/4885DRD2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.